Loading...
•
Sep 30, 2021
Verve Therapeutics Q3 2021 Earnings Report
Reported pipeline progress and financial results for the third quarter of 2021.
Key Takeaways
Verve Therapeutics reported a net loss of $22.7 million for the third quarter of 2021, with cash, cash equivalents, and marketable securities totaling $389.2 million as of September 30, 2021. The company's pipeline progress includes VERVE-101 clinical initiation on track for 2022 and preclinical data highlighting liver-targeted delivery with proprietary GalNAc-LNP Technology.
VERVE-101 clinical initiation is on track for 2022, supported by data demonstrating potent and durable lowering of PCSK9 protein and LDL-C in non-human primates.
Preclinical data highlights the development of a potent, in vivo liver-targeting lipid nanoparticle (LNP) delivery technology using a novel GalNAc-targeting ligand.
Verve ended the third quarter of 2021 with $389.2 million in cash, cash equivalents, and marketable securities.
Research and development expenses increased to $17.5 million for the third quarter of 2021, driven by additional investment in preclinical studies and manufacturing activities.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...